Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 18 April 2026
2019-05-23 10:33:00 Thursday ET

Berkeley professor and economist Barry Eichengreen reconciles the nominal and real interest rates to argue in favor of greater fiscal deficits. French econo
2018-01-02 12:39:00 Tuesday ET

Goldman Sachs takes a $5 billion net income hit that results from its offshore cash repatriation under the new Trump tax law. This income hit reflects 10%-1
2019-12-04 14:35:00 Wednesday ET

Many billionaires choose to live below their means with frugal habits and lifestyles. Those people who consistently commit to saving more, spending less, an
2017-01-03 03:26:00 Tuesday ET

President-Elect Donald Trump wants Apple and its tech peers to consider better and greater high-tech job creation in America. Apple has asked its primary
2022-10-25 11:31:00 Tuesday ET

Corporate investment insights from mergers and acquisitions Relative market misvaluation between the bidder and target firms drives most waves of mergers
2018-07-03 11:42:00 Tuesday ET

President Trump's current trade policies appear like the Reagan administration's protectionist trade policies back in the 1980s. In comparison to th